Q2 – 2018 Newsletter

Dear Friends of Bexion



The Phase Ia rising dose portion of the Phase I BXQ-350 trial has shown preliminary clinical activity in adult patients who had previously been treated for recurrent high-grade gliomas and advanced solid tumors. BXQ-350 was well-tolerated across the dose ranges tested and no drug-related Dose Limiting Toxicities (DLTs) or Severe Adverse Events (SAEs) were reported. Best response were observed in 7 patients completing to day 113 including 1 high grade glioma patient at the lowest dose has stable disease >19 months.
Bexion continues to dose adult patients in the Phase Ib portion of this trial.


Bexion is planning a Pediatric Phase I Trial for Solid Tumors with Nationwide Children’s Hospital in Columbus, OH. Cincinnati Children’s Hospital and Medical Center (CCHMC) could be the second site conducting this trial. The first patient is expected to be dosed in Q3 2018.
An Adult Phase II Trial for GBM with BXQ-350 in combination is being planned. Initial sites likely could include our Phase I sites, University of New Mexico, University of Cincinnati, University of Kentucky and the Ohio State University.


Bexion is happy to announce the addition of Jean-Pierre Bizzari, MD as a strategic consultant. Dr. Bizzari served as Executive Vice-President, Group Head, Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. His career at Celgene includes several major accomplishments including the development and approval of oncology products including REVLIMID®* (lenalidomide), VIDAZA®* (azacitidine), ISTODAX®* (romidepsin) and ABRAXANE®* (nab-paclitaxel). During his prestigious career, Dr. Bizzari has been involved in the development of several anti-cancer treatments such as TAXOTERE (docetaxel), Camptosar®* (CPT -11) or ELOXATIN®* (Oxaliplatin) and actively involved in the vaccination and gene therapy research. He has written more than 70 articles in peer review journals and about 170 abstracts for scientific congresses. Claude Jaquillat Prize winner in 2013, he is undoubtedly a world-renowned expert in oncology.
*Registered trademarks of respective owners.

Bexion Chosen to Present


The Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has chosen Bexion’s scientific abstract titled “First-in-human, first-in-class phase Ia study of BXQ-350 for solid tumors and gliomas” for presentation in the Poster Discussion Session of the ASCO annual meeting to be held in Chicago in early June. The ASCO Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. An additional three Bexion abstracts will be included online in the 2018 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement. ASCO’s acceptance rate is historically about 12%. All four of Bexion’s submissions were accepted, which is remarkable given that this is the first time Bexion has submitted material to ASCO.


Bexion was one of fifteen early stage, privately held companies hand-picked by BioCentury to present at their 25th Annual Future Leaders in the Biotech Industry on March 23, 2018. Bexion’s Founder and CEO, Dr. Ray Takigiku showcased the company in the opening slot of the “Next Wave” track at the meeting.
More than 500 delegates congregated at Future Leaders, representing top financial institutions, pharmaceutical business development executives and high net worth investors.

The World Orphan Drug Congress USA convenes at the Gaylord National Harbor Hotel in Maryland April 25-27, 2018, a global gathering of 1,000 leaders in orphan drugs from 38 countries, and over 135 presentations covering all aspects of orphan drug development and rare disease research.
Bexion is one of 30 companies that have been chosen to participate in this event.

Bexion Pharmaceuticals was chosen to present at the upcoming Landmark Alternate Asset form on May 8, 2018 to be held in Greenwich, CT. Bexion will be one of 15 companies presenting to 45-50 investors including Family Offices, angel and high net worth investors.


Bexion has increased the Series B open round from $10MM to $15MM.
If you are interested in participating in this round, please contact Margaret van Gilse; mvangilse@bexionpharma.com

If you have questions, please contact: Margaret van Gilse (859) 757-1652 mvangilse@bexionpharma.com

This newsletter contains forward-looking statements that are current at the time of release. The company’s plans may change depending on, for example, clinical results, drug availability, and finances.
Saving Live

2018-08-11T16:47:41+00:00 April 9th, 2018|